title: Great Health Benefits But No Change in Employment or Psychopharmaceutical Drug Use 2 Years After Roux-en-Y Gastric Bypass.
abstract: BACKGROUND
  The aim was to examine health benefits and lifestyle factors after Roux-en-Y gastric bypass (RYGB).
  
  
  METHODS
  Patients (n = 165) were investigated 2 years after RYGB in relation to psychopharmaceutical drugs, employment status, type 2 diabetes mellitus (T2DM), hypertension, metabolic syndrome (MetS), body weight, physical activity (PA), and energy intake.
  
  
  RESULTS
  Excess weight loss (EWL) was 71.4 ± 20.6 %. Prevalence of T2DM, hypertension, and MetS was reduced (P < 0.001 for all). There were no changes in the use of psychopharmaceutical drugs (20.6 vs. 18.8 %, P = 0.549) or in the proportion of unemployed participants (37.7 vs. 33.3 %, P = 0.189) from pre- to post-surgery. Eighty-three percent achieved EWL ≥ 50 %. These subjects had a lower pre-surgery BMI. We found no differences in the prevalence of hypertension, T2DM, and MetS pre-surgery, but the prevalence was lower after surgery compared with subjects with EWL < 50 %.
  
  
  CONCLUSIONS
  RYGB induced remission of T2DM, hypertension, and MetS 2 years after surgery. The benefit was greatest in the group with EWL ≥ 50 %. Despite excellent weight loss, there was no change in the use of psychopharmaceutical drugs or proportion of unemployed participants.
authors: Division of Medicine, Department of Clinical Service, Section of Nutrition and Dietetics, Oslo University Hospital Aker, Oslo, Norway, susanna@hanvold.no.
authors: Susanna E
authors: SE
authors: Hanvold
authors: Elin B
authors: EB
authors: Løken
authors: Sofie F
authors: SF
authors: Paus
authors: Eva Rustad
authors: ER
authors: de Brisis
authors: Kirsti
authors: K
authors: Bjerkan
authors: Helga
authors: H
authors: Refsum
authors: Anne-Marie
authors: AM
authors: Aas
mesh_terms: D000328:Adult; D015897:Comorbidity; D004651:Employment / Q000706:statistics & numerical data; D005260:Female; D005500:Follow-Up Studies; D015390:Gastric Bypass / Q000706:statistics & numerical data*; D006304:Health Status; D006801:Humans; D008019:Life Style; D008297:Male; D008875:Middle Aged; D009767:Obesity, Morbid / Q000601:surgery*; D011619:Psychotropic Drugs; D016032:Randomized Controlled Trials as Topic; D015431:Weight Loss
chemical_list: D011619:Psychotropic Drugs
references: Surg Obes Relat Dis. 2012 May-Jun;8(3):269-74
references: 21723203
references: Ann Intern Med. 2011 Sep 6;155(5):281-91
references: 21893621
references: Nutrition. 2012 Jan;28(1):53-8
references: 21885246
references: Int J Obes (Lond). 2010 Mar;34(3):437-45
references: 20010905
references: Eur J Clin Nutr. 2013 Feb;67(2):168-73
references: 23299713
references: PLoS One. 2013;8(2):e55542
references: 23418444
references: N Engl J Med. 2004 Dec 23;351(26):2683-93
references: 15616203
references: Surg Obes Relat Dis. 2014 Jan-Feb;10(1):71-8
references: 24182445
references: JAMA Surg. 2014 Mar;149(3):275-87
references: 24352617
references: Ann Surg. 2013 Oct;258(4):628-36; discussion 636-7
references: 24018646
references: Arch Surg. 2007 Oct;142(10):935-40; discussion 941
references: 17938305
references: Obes Surg. 2005 Aug;15(7):1034-9
references: 16105403
references: Obesity (Silver Spring). 2014 Aug;22(8):1799-806
references: 24634371
references: Obes Surg. 2012 Nov;22(11):1734-41
references: 23011461
references: Med Sci Sports Exerc. 2011 Aug;43(8):1575-81
references: 21681120
references: JAMA. 2012 Jan 4;307(1):56-65
references: 22215166
references: Obes Surg. 2007 Apr;17(4):434-7
references: 17608252
references: Am J Clin Nutr. 2010 Oct;92(4):704-13
references: 20739420
references: J Am Diet Assoc. 2010 Apr;110(4):527-34
references: 20338278
references: Obes Surg. 2012 Apr;22(4):530-5
references: 21901283
references: Obes Facts. 2010 Feb;3(1):33-40
references: 20215793
references: Aust N Z J Surg. 1990 Oct;60(10):755-8
references: 2206119
references: Obes Surg. 2006 Jul;16(7):859-64
references: 16839483
references: Surg Obes Relat Dis. 2012 Sep-Oct;8(5):548-55
references: 22721581